SCM
TSHA icon

Suvretta Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Suvretta Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,217,449
Closed -$7.43M – 105
2025
Q2 		$7.43M Buy
+3,217,449
New +$6.99M 0.22% 56

Other funds holding TSHA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Suvretta Capital Management's TSHA Position: Q3 2025 in Review

Suvretta Capital Management sold out of Taysha Gene Therapies (TSHA) in Q3 2025, closing a stake of 3,217,449 shares — an estimated $7.43M sold.

Suvretta Capital Management first reported a position in TSHA in Q2 2025 and held it in 1 quarter. The position peaked at $7.43M in Q2 2025. 155 funds tracked by Wall St. Rank hold TSHA as of Q3 2025.

  • Suvretta Capital Management reported no remaining Taysha Gene Therapies position as of Q3 2025 after selling out during the quarter.
  • Suvretta Capital Management sold 3,217,449 Taysha Gene Therapies shares in Q3 2025, an estimated $7.43M.
  • Suvretta Capital Management first reported a position in Taysha Gene Therapies in Q2 2025 and held it in 1 quarter.
  • Suvretta Capital Management's Taysha Gene Therapies position peaked at $7.43M in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2025.

Based on Suvretta Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.